A range of univariate sensitivity analyses have been explored

Sensitivity analyses	Description	Abbreviated
SA01	Base case	Base case
SA02	Amgen STARs costing	Amgen STARs
SA03	Amgen NMA results	Amgen NMA
SA04	Amgen STARs costings and NMA results	Amgen STARs+NMA
SA05	No HRQoL step change for naive to experienced	No naive util step
SA06	SCC permanent utility effect of the average P1–P5 decrement	SCC ongoing mean
SA07	SCC permanent utility effect of the maximum P1-P5 decrement	SCC ongoing max.
SA08	No general mortality	No gen. mortality
SA09	5-year horizon	5-year horizon
SA10	2-year horizon	2-year horizon
SA11	vdHOUT utility multipliers	vd Hout utility
SA12	QoL impact SAEs ONJ and renal cohort average survival, not the measured trial duration	SAE P1+
SA13	Excluding SAEs	No SAE
SA14	No general discontinuations	No gen. discs.
SA15	No discontinuations	No discs.
SA16	AG TTF functional form from NAIVE for breast and prostate	TTF form AG naive
SA17	AG TTF functional form all patients for breast, prostate and OSTL	TTF form AG all patients

These are presented for the four cancer groupings: breast, prostate and OST including lung (OSTL). They are also presented for the three patient groups of all, naive and experienced, coupled with the split between applying the pooled HRs and RRs and the SRE-specific HRs and RRs for breast prostate and OSTL. The summaries that follow all show the net impact of denosumab on total amounts. The costs reported are the total costs including SRE costs and SAE costs; for example, the cost associated with BSC excluding PAS is the additional cost of using denosumab compared with BSC. These sensitivity analyses are presented only for the analyses that apply the pooled HRs and RRs. The parallel sensitivity analyses that present them for the analyses that apply the SRE experience subgroup-specific HRs and RRs are available on demand from the AG.

The probabilistic analyses were run over 2000 iterations. As a cross-check the ALL PATIENT probabilistic modelling was re-run with 10,000 iterations, with results being near identical to those of the run with 2000 iterations.

	oreast cancer
	2
	lyses:
	σ
	20
	>
2	Ξ.
	5
	P
	S
	2
	Ð
,	Ţ
	σ
	S.
•	4
2	

Breast	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£6242	£4292	-0.988	0.027	£229,547	£157,829	£1707	-£243	-0.211	0.007	£245,264	Dominant
Amgen STARs	£6623	£4673	-0.988	0.027	£243,559	£171,841	£1782	-£168	-0.211	0.007	£255,996	Dominant
Amgen NMA	£6324	£4374	-0.922	0.025	£257,431	£178,053	£1705	-£245	-0.213	0.007	£242,776	Dominant
Amgen STARs+NMA	£6683	£4733	-0.922	0.025	£272,032	£192,655	£1781	-£170	-0.213	0.007	£253,470	Dominant
No naive util step	£6242	£4292	-0.988	0.017	£366,760	£252,172	£1707	-£243	-0.211	0.005	£362,999	Dominant
SCC ongoing mean	£6242	£4292	-0.988	0.033	£189,204	£130,090	£1707	-£243	-0.211	0.008	£208,302	Dominant
SCC ongoing max.	£6242	£4292	-0.988	0.035	£179,091	£123,137	£1707	-£243	-0.211	600.0	£198,682	Dominant
No gen. mortality	£6277	£4316	-0.996	0.027	£228,819	£157,307	£1717	-£245	-0.213	0.007	£244,512	Dominant
5-year horizon	£6102	£4204	-0.935	0.025	£239,758	£165,176	£1670	-£229	-0.199	0.007	£256,441	Dominant
2-year horizon	£4781	£3319	-0.653	0.016	£291,409	£202,319	£1309	-£153	-0.139	0.004	£308,247	Dominant

Breast	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
vd Hout utility	£6242	£4292	-0.988	0.025	£249,169	£171,320	£1707	-£243	-0.211	0.006	£266,094	Dominant
SAE P1+	£6242	£4292	-0.988	0.026	£242,970	£167,058	£1707	-£243	-0.211	0.013	£134,378	Dominant
No SAE	£6276	£4300	-1.001	0.028	£224,711	£153,953	£1773	-f203	-0.214	0.006	£291,955	Dominant
No gen. discs.	£11,493	£7912	-1.841	0.046	£251,628	£173,216	£3167	—£414	-0.400	0.012	£259,902	Dominant
No discs.	£11,744	£8085	-1.883	0.047	£252,493	£173,819	£3237	-£422	-0.409	0.012	£260,510	Dominant
TTF form AG naive	f6235	£4285	-0.994	0.028	£225,904	£155,252	£1707	-£243	-0.211	0.007	£244,209	Dominant
TTF form AG all	£6147	£4197	-1.060	0.030	£205,611	£140,382	£1687	-f263	-0.227	0.008	£222,101	Dominant

Breast	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
SRE naive	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	f6308	£4358	-0.962	0.035	£181,092	£125,109	£1747	-£203	-0.186	0.008	£209,345	Dominant
Amgen STARs	£6674	£4724	-0.962	0.035	£191,585	£135,602	£1812	-£138	-0.186	0.008	£217,069	Dominant
Amgen NMA	£6432	£4482	-0.863	0.031	£210,330	£146,564	£1745	-£205	-0.189	0.008	£206,251	Dominant
Amgen STARs+NMA	£6764	£4814	-0.863	0.031	£221,185	£157,419	£1810	-£140	-0.189	0.008	£213,963	Dominant
No naive util step	£6308	£4358	-0.962	0.018	£358,586	£247,732	£1747	-£203	-0.186	0.005	£386,508	Dominant
SCC ongoing mean	f6308	£4358	-0.962	0.040	£157,346	£108,704	£1747	-£203	-0.186	0.009	£187,157	Dominant
SCC ongoing max.	£6308	£4358	-0.962	0.042	£150,985	£104,309	£1747	-£203	-0.186	0.010	£180,993	Dominant
No gen. mortality	f6343	£4381	-0.970	0.035	£180,337	£124,558	£1757	-£205	-0.188	0.008	£208,454	Dominant
5-year horizon	£6185	£4287	-0.895	0.032	£192,083	£133,134	£1714	-£185	-0.172	0.008	£223,148	Dominant

Breast	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
SRE naive	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
2-year horizon	£4902	£3441	-0.585	0.020	£250,927	£176,109	£1355	-£106	-0.109	0.005	£292,125	Dominant
vd Hout utility	£6308	£4358	-0.962	0.032	£196,932	£136,052	£1747	-f203	-0.186	0.008	£227,647	Dominant
SAE P1+	£6308	£4358	-0.962	0.033	£189,253	£130,747	£1747	-f203	-0.186	0.014	£124,016	Dominant
No SAE	£6344	£4367	-0.974	0.036	£178,058	£122,590	£1814	-£162	-0.189	0.007	£242,829	Dominant
No gen. discs.	£11,657	£8075	-1.750	0.056	£208,350	£144,337	£3251	-f331	-0.344	0.014	£231,276	Dominant
No discs.	£11,913	f8253	-1.788	0.057	£209,438	£145,104	£3323	-f336	-0.351	0.014	£232,177	Dominant
TTF form AG naive	£6297	£4347	-0.971	0.036	£177,244	£122,356	£1748	-£202	-0.186	0.008	£208,080	Dominant
TTF form AG all	£6148	£4198	-1.083	0.039	£155,959	£106,487	£1713	-£237	-0.213	0.009	£181,811	Dominant

Breast	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
SRE experienced	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£6146	£4196	-1.025	0.016	£379,539	£259,113	£1649	-£301	-0.247	0.005	£332,185	Dominant
Amgen STARs	£6549	£4599	-1.025	0.016	£404,445	£284,020	£1738	-£212	-0.247	0.005	£350,196	Dominant
Amgen NMA	£6169	£4219	-1.008	0.016	£387,700	£265,144	£1649	-f301	-0.247	0.005	£332,393	Dominant
Amgen STARs+NMA	£6566	£4616	-1.008	0.016	£412,664	£290,108	£1738	-£212	-0.247	0.005	£350,402	Dominant
No naive util step	Ι	I	I	I	Ι	I	I	I	I	I	I	I
SCC ongoing mean	£6146	£4196	-1.025	0.023	£269,923	£184,278	£1649	-£301	-0.247	0.007	£251,665	Dominant
SCC ongoing max.	£6146	£4196	-1.025	0.025	£247,002	£168,630	£1649	-f301	-0.247	0.007	£233,481	Dominant
No gen. mortality	£6183	£4221	-1.032	0.016	£379,385	£259,009	£1659	-f303	-0.249	0.005	£332,076	Dominant
5-year horizon	f5982	£4084	-0.993	0.016	£380,130	£259,517	£1606	-f292	-0.240	0.005	£332,629	Dominant
2-year horizon	£4607	£3145	-0.751	0.012	£387,023	£264,223	£1241	-£221	-0.182	0.004	£337,521	Dominant
vd Hout utility	£6146	£4196	-1.025	0.015	£409,664	£279,680	£1649	-f301	-0.247	0.005	£358,405	Dominant
SAE P1+	£6146	£4196	-1.025	0.015	£418,347	£285,608	£1649	-£301	-0.247	0.011	£154,000	Dominant
No SAE	£6178	£4202	-1.040	0.017	£366,663	£249,381	£1714	-f262	-0.251	0.004	£421,982	Dominant
No gen. discs.	£11,257	£7676	-1.973	0.031	£364,430	£248,487	£3047	-f535	-0.481	0.009	£320,879	Dominant
No discs.	£11,501	£7842	-2.020	0.032	£364,043	£248,215	£3114	-f546	-0.492	0.010	£320,590	Dominant
TTF form AG naive	I	I	I	I	I	I	I	I	I	I	I	I
TTF form AG all	Ι	I	I	I	I	I	I	I	I	I	I	I

U
9
σ
U
6)
Ľ.
D
÷
S
0
0
1.2
S
Q
S
~
Č
6
<u>.</u>
5
Ξ.
S
2
0
S
(۵)
Ť.
O
٠ ٣ ٠

Prostate	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£3951	£2766	-0.543	0.035	£112,415	£78,713	£1059	-£125	-0.130	0.009	£111,603	Dominant
Amgen STARs	£4179	£2995	-0.543	0.035	£118,915	£85,213	£1106	-£79	-0.130	0.009	£116,525	Dominant
Amgen NMA	£3948	£2764	-0.546	0.035	£111,558	£78,091	£1060	-£124	-0.129	0.009	£112,659	Dominant
Amgen STARs+NMA	£4177	£2993	-0.546	0.035	£118,030	£84,563	£1107	-£78	-0.129	0.009	£117,594	Dominant
No naive util step	£3951	£2766	-0.543	0.026	£153,522	£107,497	£1059	-£125	-0.130	0.007	£159,704	Dominant
SCC ongoing mean	£3951	£2766	-0.543	0.046	£85,204	£59,660	£1059	-£125	-0.130	0.012	£86,925	Dominant
SCC ongoing max.	£3951	£2766	-0.543	0.054	£73,053	£51,152	£1059	-£125	-0.130	0.014	£75,460	Dominant
No gen. mortality	£4037	£2825	-0.560	0.036	£110,722	£77,494	£1081	-£131	-0.134	0.010	£109,732	Dominant
5-year horizon	£3941	£2761	-0.537	0.035	£113,896	£79,787	£1057	-f123	-0.129	0.009	£113,427	Dominant
2-year horizon	£3591	£2524	-0.454	0.028	£127,528	£89,659	£973	-f93	-0.109	0.008	£129,289	Dominant
vd Hout utility	£3951	£2766	-0.543	0.031	£128,929	£90,277	£1059	-£125	-0.130	0.008	£127,983	Dominant

Prostate	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
SAE P1 +	£3951	£2766	-0.543	0.021	£187,561	£131,331	£1059	-£125	-0.130	0.010	£106,232	Dominant
No SAE	£3963	£2754	-0.556	0.038	£103,941	£72,218	£1081	-£129	-0.138	0.010	£106,466	Dominant
No gen. discs.	£7529	£5270	-1.073	0.064	£118,284	£82,795	£2011	-£248	-0.246	0.017	£119,642	Dominant
No discs.	£7831	£5481	-1.119	0.066	£118,739	£83,114	£2198	-£152	-0.273	0.018	£120,679	Dominant
TTF form AG naive	£3968	£2784	-0.528	0.034	£116,636	£81,823	£1065	-£120	-0.125	0.009	£116,751	Dominant
TTF form AG all	£3939	£2755	-0.553	0.036	£109,826	£76,803	£1056	-£129	-0.133	0.010	£108,797	Dominant

Prostate	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
SRE naive	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£3969	£2785	-0.528	0.039	£103,003	£72,269	£1061	-£123	-0.129	0.011	£99,561	Dominant
Amgen STARs	£4195	£3010	-0.528	0.039	£108,848	£78,114	£1107	-£77	-0.129	0.011	£103,929	Dominant
Amgen NMA	£3965	£2780	-0.532	0.039	£101,900	£71,460	£1062	-£122	-0.128	0.011	£100,547	Dominant
Amgen STARs+NMA	£4191	£3007	-0.532	0.039	£107,716	£77,276	£1108	-£76	-0.128	0.011	£104,926	Dominant
No naive util step	£3969	£2785	-0.528	0.026	£153,733	£107,862	£1061	-£123	-0.129	0.007	£156,150	Dominant
SCC ongoing mean	£3969	£2785	-0.528	0.049	£80,415	£56,420	£1061	-£123	-0.129	0.013	£79,802	Dominant
SCC ongoing max.	£3969	£2785	-0.528	0.057	£69,884	£49,032	£1061	-£123	-0.129	0.015	£70,226	Dominant
No gen. mortality	£4054	£2843	-0.546	0.040	£101,176	£70,945	£1082	-£129	-0.133	0.011	£97,612	Dominant
5-year horizon	£3961	£2781	-0.520	0.038	£104,689	£73,497	£1060	-£120	-0.126	0.010	£101,544	Dominant
2-year horizon	£3620	£2553	-0.429	0.030	£120,521	£85,018	£99	-£88	-0.105	0.008	£119,210	Dominant
vd Hout utility	£3969	£2785	-0.528	0.034	£118,235	£82,955	£1061	-£123	-0.129	0.009	£114,266	Dominant
SAE P1+	£3969	£2785	-0.528	0.024	£162,306	£113,877	£1061	-£123	-0.129	0.011	£95,272	Dominant
No SAE	£3983	£2773	-0.540	0.042	£95,819	£66,716	£1083	-£126	-0.136	0.011	£95,462	Dominant
No gen. discs.	£7571	£5312	-1.037	0.068	£111,073	£77,935	£2020	-£239	-0.239	0.018	£109,544	Dominant
No discs.	£7875	£5526	-1.081	0.071	£111,674	£78,358	£2208	-£142	-0.265	0.020	£111,053	Dominant
TTF form AG naive	£3993	£2809	-0.507	0.037	£107,860	£75,867	£1069	-£116	-0.122	0.010	£105,215	Dominant
TTF form AG all	£3953	f2769	-0.541	0.040	£100,060	£70,085	£1057	£128	-0.132	0.011	£96,521	Dominant

Prostate	BSC	BSC	BSC	BSC	BSC	BSC	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid	Zoledronic acid
SRE experienced	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£3897	£2713	-0.587	0.025	£152,916	£106,446	£1053	-£131	-0.135	0.006	£170,854	Dominant
Amgen STARs	£4135	£2950	-0.587	0.025	£162,234	£115,764	£1100	-£84	-0.135	0.006	£178,502	Dominant
Amgen NMA	£3900	£2716	-0.584	0.025	£153,710	£107,034	£1054	-£130	-0.134	0.006	£172,124	Dominant
Amgen STARs+NMA	£4137	£2953	-0.584	0.025	£163,045	£116,368	£1101	-f83	-0.134	0.006	£179,785	Dominant
No naive util step	Ι	I	I	I	I	I	I	I	I	Ι	I	I
SCC ongoing mean	£3897	£2713	-0.587	0.038	£102,981	£71,686	£1053	-£131	-0.135	0.009	£116,820	Dominant
SCC ongoing max.	£3897	£2713	-0.587	0.046	£84,108	£58,549	£1053	-£131	-0.135	0.011	£95,965	Dominant
No gen. mortality	f3986	£2775	-0.601	0.026	£152,326	£106,035	£1076	-£135	-0.138	0.006	£170,261	Dominant
5-year horizon	f3884	£2703	-0.584	0.025	£152,944	£106,466	£1050	-£130	-0.135	0.006	£170,852	Dominant
2-year horizon	£3509	£2442	-0.524	0.023	£153,779	£107,047	£959	-£108	-0.122	0.006	£171,394	Dominant
vd Hout utility	f3897	£2713	-0.587	0.022	£174,747	£121,643	£1053	-£131	-0.135	0.005	£195,155	Dominant
SAE P1+	£3897	£2713	-0.587	0.011	£341,668	£237,838	£1053	-£131	-0.135	0.007	£158,518	Dominant
No SAE	£3909	£2699	-0.600	0.028	£137,816	£95,166	£1074	-£135	-0.143	0.007	£159,100	Dominant
No gen. discs.	£7408	£5149	-1.176	0.051	£145,820	£101,357	£1987	-£272	-0.267	0.012	£163,163	Dominant
No discs.	£7704	£5355	-1.227	0.053	£145,522	£101,143	£2169	-£180	-0.298	0.013	£161,126	Dominant
TTF form AG naive	I	I	I	I	I	I	I	I	I	I	I	I
TTF form AG all	I	I	I	I	I	I	I	I	I	I	I	I

		•										
OST + NSCLC	BSC						Zoledronic	acid				
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2548	£1766	-0.288	0.017	£147,122	£101,986	£836	£54	-0.092	0.006	£139,739	£9004
Amgen STARs	£2676	£1894	-0.288	0.017	£154,479	£109,343	£859	£78	-0.092	0.006	£143,729	£12,994
Amgen NMA	£2567	£1786	-0.276	0.016	£156,113	£108,578	£837	£56	-0.091	0.006	£141,762	£9432
Amgen STARs+NMA	£2690	£1909	-0.276	0.016	£163,599	£116,063	£861	£79	-0.091	0.006	£145,729	£13,399
No naive util step	£2548	£1766	-0.288	0.015	£175,401	£121,589	£836	£54	-0.092	0.005	£162,929	£10,498
SCC ongoing mean	£2548	£1766	-0.288	0.020	£126,620	£87,774	£836	£54	-0.092	0.007	£120,980	£7795
SCC ongoing max.	£2548	£1766	-0.288	0.022	£113,410	£78,617	£836	£54	-0.092	0.008	£108,775	£7008
No gen. mortality	£2557	£1772	-0.289	0.017	£146,781	£101,744	£839	£54	-0.093	0.006	£139,429	£9057
5-year horizon	£2548	£1767	-0.286	0.017	£148,914	£103,282	£834	£54	-0.091	0.006	£141,622	£9121
2-year horizon	£2443	£1698	-0.267	0.016	£156,692	£108,877	£781	£36	-0.083	0.005	£148,731	f6827
vd Hout utility	£2548	£1766	-0.288	0.014	£177,567	£123,091	£836	£54	-0.092	0.005	£168,010	£10,825
SAE P1+	£2548	£1766	-0.288	0.014	£188,601	£130,740	£836	£54	-0.092	0.010	£87,426	£5633
No SAE	£2535	£1747	-0.290	0.018	£139,278	£95,988	£834	£46	-0.093	0.006	£143,426	£7867
No gen. discs.	£6004	£4173	-0.677	0.038	£157,753	£109,654	£1619	-£211	-0.183	0.012	£138,680	Dominant
No discs.	£6150	£4275	-0.694	0.039	£158,204	£109,980	£1686	-£189	-0.190	0.012	£139,541	Dominant
TTF form AG naive	I	I	I	I	I	I	I	I	I	I	I	I
TTF form AG all	£2549	£1767	-0.286	0.017	£147,049	£101,951	£838	£56	-0.090	0.006	£142,626	£9591

Univariate sensitivity analyses: other solid tumours plus non-small cell lung cancer

OST + NSCLC	BSC						Zoledronic a	ıcid				
SRE naive	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2473	£1691	-0.343	0.024	£103,350	£70,679	£823	£41	-0.103	0.008	£106,812	£5337
Amgen STARs	£2618	£1836	-0.343	0.024	£109,409	£76,737	£850	£68	-0.103	0.008	£110,310	£8834
Amgen NMA	£2509	£1727	-0.320	0.022	£112,789	£77,644	£825	£43	-0.102	0.008	£108,515	£5702
Amgen STARs+NMA	£2646	£1864	-0.320	0.022	£118,943	f83,798	£852	£70	-0.102	0.008	£111,992	£9179
No naive util step	£2473	£1691	-0.343	0.018	£135,660	£92,775	£823	£41	-0.103	0.006	£137,904	£6890
SCC ongoing mean	£2473	£1691	-0.343	0.027	£90,853	£62,132	£823	£41	-0.103	0.009	£94,286	£4711
SCC ongoing max.	£2473	£1691	-0.343	0.030	£82,514	£56,429	f823	£41	-0.103	0.010	£85,870	£4290
No gen. mortality	£2481	£1696	-0.344	0.024	£103,033	£70,452	£826	£42	-0.104	0.008	£106,469	£5359
5-year horizon	£2476	£1695	-0.338	0.024	£105,289	£72,086	f823	£42	-0.101	0.008	£109,190	£5606
2-year horizon	£2385	£1639	-0.311	0.021	£113,714	£78,167	£775	£29	-0.090	0.007	£118,569	£4448
vd Hout utility	£2473	£1691	-0.343	0.020	£124,310	£85,013	f823	£41	-0.103	0.006	£127,857	f6388
SAE P1+	£2473	£1691	-0.343	0.020	£122,918	£84,061	f823	£41	-0.103	0.011	£72,937	£3644
No SAE	£2459	£1671	-0.345	0.025	£98,978	£67,269	£821	£33	-0.104	0.008	£108,627	£4347
No gen. discs.	£5895	£4064	-0.760	0.049	£120,402	£83,010	£1608	-f222	-0.194	0.014	£113,154	Dominant
No discs.	£6040	£4165	-0.777	0.050	£121,082	£83,502	£1675	-f200	-0.202	0.015	£114,173	Dominant
TTF form AG naive	I	I	I	I	I	I	1	I	1	I	1	I
TTF form AG all	£2475	£1693	-0.339	0.024	£103,297	£70,666	f828	£46	-0.099	0.007	£110,506	£6173

OST + NSCLC	BSC						Zoledronic a	ıcid				
SRE experienced	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2620	£1839	-0.235	0.011	£238,840	£167,587	£848	£66	-0.082	0.004	£196,114	£15,282
Amgen STARs	£2731	£1949	-0.235	0.011	£248,919	£177,666	f869	f87	-0.082	0.004	£200,948	£20,115
Amgen NMA	£2624	£1842	-0.234	0.011	£241,247	£169,366	£849	f68	-0.081	0.004	£198,534	£15,801
Amgen STARs+NMA	£2734	£1952	-0.234	0.011	£251,348	£179,467	£870	f88	-0.081	0.004	£203,338	£20,606
No naive util step	Ι	Ι	I	I	I	Ι	Ι	Ι	I	Ι	Ι	I
SCC ongoing mean	£2620	£1839	-0.235	0.013	£196,905	£138,162	£848	£66	-0.082	0.005	£164,375	£12,808
SCC ongoing max.	£2620	£1839	-0.235	0.015	£171,707	£120,482	£848	£66	-0.082	0.006	£144,789	£11,282
No gen. mortality	£2630	£1845	-0.236	0.011	£238,622	£167,434	£851	£67	-0.082	0.004	£195,987	£15,403
5-year horizon	£2617	£1836	-0.235	0.011	£238,875	£167,612	£845	f65	-0.082	0.004	£196,090	£15,025
2-year horizon	£2499	£1753	-0.224	0.010	£239,796	£168,258	£788	£42	-0.076	0.004	£195,766	£10,537
vd Hout utility	£2620	£1839	-0.235	0.009	£290,357	£203,735	f848	f66	-0.082	0.004	£237,589	£18,514
SAE P1+	£2620	£1839	-0.235	0.007	£365,867	£256,718	£848	f66	-0.082	0.008	£107,304	£8361
No SAE	£2607	£1820	-0.237	0.012	£220,707	£154,020	£846	f58	-0.083	0.004	£204,488	£14,044
No gen. discs.	£6109	£4278	-0.598	0.028	£221,438	£155,082	£1630	-£201	-0.172	0.009	£176,418	Dominant
No discs.	£6256	£4381	-0.614	0.028	£221,084	£154,830	£1696	-£178	-0.179	0.010	£176,813	Dominant
TTF form AG naive	I	I	I	I	I	I	Ι	Ι	I	Ι	I	I
TTF form AG all	I	I	I	I	Ι	I	I	I	I	I	I	I

Univariate sensitivity analyses: non-small cell lung cancer

Lung	BSC					Zoledronic	acid					
All patients	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2262	£1583	-0.218	0.012	£191,412	£133,926	£708	f28	-0.076	0.005	£149,878	£5972
Amgen STARs	£2362	£1683	-0.218	0.012	£199,870	£142,383	£727	£47	-0.076	0.005	£153,881	£9976
Amgen NMA	£2262	£1583	-0.218	0.012	£191,412	£133,926	£708	f28	-0.076	0.005	£149,878	£5972
Amgen STARs+NMA	£2362	£1683	-0.218	0.012	£199,870	£142,383	£727	£47	-0.076	0.005	£153,881	£9976
No naive util step	£2262	£1583	-0.218	0.010	£218,252	£152,705	£708	£28	-0.076	0.004	£172,919	£6891
SCC ongoing mean	£2262	£1583	-0.218	0.013	£178,698	£125,030	£708	£28	-0.076	0.005	£141,287	£5630
SCC ongoing max.	£2262	£1583	-0.218	0.013	£169,299	£118,454	£708	£28	-0.076	0.005	£134,827	£5373
No gen. mortality	£2269	£1587	-0.219	0.012	£191,156	£133,744	£710	£29	-0.076	0.005	£149,719	£6022
5-year horizon	£2262	£1583	-0.218	0.012	£191,529	£134,010	£708	f28	-0.076	0.005	£149,985	£5982
2-year horizon	£227	£1560	-0.212	0.011	£196,245	£137,432	£691	f23	-0.073	0.004	£153,552	£5156
vd Hout utility	£2262	£1583	-0.218	0.009	£247,875	£173,431	£708	f28	-0.076	0.004	£194,185	£7738
SAE P1+	£2262	£1583	-0.218	0.010	£219,997	£153,926	£708	f28	-0.076	0.006	£112,981	£4502
No SAE	£2248	£1564	-0.220	0.013	£179,389	£124,828	£704	£21	-0.076	0.005	£155,322	£4534
No gen. discs.	£3848	£2700	-0.357	0.018	£208,396	£146,237	£1038	-£110	-0.104	0.007	£159,202	Dominant
No discs.	f3888	£2728	-0.360	0.019	£208,716	£146,469	£1056	-£103	-0.105	0.007	£160,025	Dominant
TTF form AG naive	I	I	I	1	I	I	I	I	I	1	I	I
TTF form AG all	1	I	I	I	I	I	I	I	I	I	I	I

Lung	BSC						Zoledronic a	acid				
SRE naive	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2257	£1578	-0.228	0.014	£158,333	£110,671	£693	£13	-0.087	0.006	£112,617	£2135
Amgen STARs	£2359	£1679	-0.228	0.014	£165,463	£117,801	£715	£36	-0.087	0.006	£116,272	£5790
Amgen NMA	£2257	£1578	-0.228	0.014	£158,333	£110,671	£693	£13	-0.087	0.006	£112,617	£2135
Amgen STARs+NMA	£2359	£1679	-0.228	0.014	£165,463	£117,801	£715	f36	-0.087	0.006	£116,272	£5790
No naive util step	£2257	£1578	-0.228	0.011	£199,936	£139,750	£693	£13	-0.087	0.005	£142,333	£2698
SCC ongoing mean	£2257	£1578	-0.228	0.015	£149,443	£104,457	£693	£13	-0.087	0.006	£107,042	£2029
SCC ongoing max.	£2257	£1578	-0.228	0.016	£142,745	£99,775	£693	£13	-0.087	0.007	£102,788	£1948
No gen. mortality	£2263	£1582	-0.228	0.014	£158,064	£110,477	£695	£13	-0.088	0.006	£112,470	£2170
5-year horizon	£2257	£1578	-0.227	0.014	£158,499	£110,792	£693	£13	-0.087	0.006	£112,748	£2151
2-year horizon	£2227	£1559	-0.218	0.013	£165,275	£115,737	£678	£10	-0.083	0.006	£117,203	£1790
vd Hout utility	£2257	£1578	-0.228	0.011	£205,154	£143,397	£693	£13	-0.087	0.005	£145,941	£2766
SAE P1+	£2257	£1578	-0.228	0.013	£177,449	£124,032	£693	£13	-0.087	0.008	£90,041	£1707
No SAE	£2243	£1559	-0.229	0.015	£149,896	£104,205	£689	£6	-0.088	0.006	£115,624	£947
No gen. discs.	£3885	£2737	-0.343	0.020	£191,622	£135,008	£1029	-£119	-0.112	0.008	£128,843	Dominant
No discs.	£3926	£2766	-0.346	0.020	£192,291	£135,497	£1048	-£112	-0.113	0.008	£129,997	Dominant
TTF form AG naive	I	I	I	I	I	I	I	I	I	I	I	I
TTF form AG all	I	I	I	I	I	I	I	I	I	I	I	I

Lung	BSC						Zoledronic a	acid				
SRE experienced	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2268	£1588	-0.210	0.009	£239,211	£167,529	£722	£43	-0.065	0.003	£215,614	£12,743
Amgen STARs	£2366	£1686	-0.210	0.009	£249,586	£177,905	£738	£58	-0.065	0.003	£220,231	£17,361
Amgen NMA	£2268	£1588	-0.210	0.009	£239,211	£167,529	£722	£43	-0.065	0.003	£215,614	£12,743
Amgen STARs+NMA	£2366	£1686	-0.210	600.0	£249,586	£177,905	£738	f58	-0.065	0.003	£220,231	£17,361
No naive util step	I	I	I	I	I	I	I	I	I	I	Ι	I
SCC ongoing mean	£2268	£1588	-0.210	0.010	£219,862	£153,979	£722	£43	-0.065	0.004	£200,348	£11,841
SCC ongoing max.	£2268	£1588	-0.210	0.011	£205,940	£144,229	£722	£43	-0.065	0.004	£189,156	£11,180
No gen. mortality	£2274	£1593	-0.210	0.010	£239,011	£167,390	£725	£43	-0.065	0.003	£215,469	£12,821
5-year horizon	£2267	£1588	-0.210	0.009	£239,211	£167,529	£722	£43	-0.065	0.003	£215,613	£12,735
2-year horizon	£2227	£1560	-0.206	0.009	£239,322	£167,607	£703	£36	-0.063	0.003	£215,451	£10,888
vd Hout utility	£2268	£1588	-0.210	0.007	£309,520	£216,770	£722	£43	-0.065	0.003	£279,244	£16,504
SAE P1+	£2268	£1588	-0.210	0.008	£285,459	£199,919	£722	£43	-0.065	0.005	£147,641	£8726
No SAE	£2253	£1569	-0.211	0.010	£220,987	£153,914	£719	£35	-0.065	0.003	£227,229	£11,032
No gen. discs.	£3813	£2665	-0.370	0.017	£227,929	£159,313	£1046	-£102	-0.096	0.005	£204,827	Dominant
No discs.	£3851	£2692	-0.374	0.017	£227,770	£159,197	£1064	-f96	-0.097	0.005	£204,801	Dominant
TTF form AG naive	I	I	I	I	I	I	I	I	1	I	I	I
TTF form AG all	I	I	I	I	I	I	I	I	I	I	I	I

Probabilistic modelling

Breast cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.822	CiC information has been removed	0.028	£4269	£154,944
Zoledronic acid	1.842	CiC information has been removed	0.007	-£243	Dominant
Denosumab	1.849	CiC information has been removed	_	_	-
Disodium pamidronate	1.840	CiC information has been removed	0.010	-£3246	Dominant

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
fO	92%	8%	0%
£20,000	98%	2%	0%
£30,000	100%	0%	0%
£40,000	100%	0%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£O	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	0%	0%	0%	100%
£100,000	13%	0%	0%	87%



FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Prostate cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.065	CiC information has been removed	0.035	£2764	£78,756
Zoledronic acid	1.091	CiC information has been removed	0.009	-£123	Dominant
Denosumab	1.100	CiC information has been removed	_	_	-

WTP/QALY	Denosumab	Zoledronic acid
£0	88%	12%
£20,000	99%	1%
£30,000	100%	0%
£40,000	100%	0%
£100,000	100%	0%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	2%	0%	98%
£100,000	73%	0%	27%



FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Other solid tumours plus non-small cell lung cancer: all patients

	QALY	£ total	Δ QALY	∆ Cost	ICER
BSC	0.701	CiC information has been removed	0.017	£1771	£102,102
Zoledronic acid	0.713	CiC information has been removed	0.006	£56	£9391
Denosumab	0.719	CiC information has been removed	-	_	_
CiC commercial-in-confidence					

WTP/QALY	Denosumab	Zoledronic acid
£O	26%	75%
£20,000	75%	25%
£30,000	88%	12%
£40,000	93%	7%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	44%	0%	56%



FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Non-small cell lung cancer: all patients

	QALY	£ total		∆ Cost	ICER
BSC	0.439	CiC information has been removed	0.012	£1582	£132,177
Zoledronic acid	0.446	CiC information has been removed	0.005	£32	£6967
Denosumab	0.451	CiC information has been removed	-	_	_
CiC, commercial-in-confidence.					

WTP/QALY	Denosumab	Zoledronic acid
£O	35%	65%
£20,000	69%	31%
£30,000	77%	23%
£40,000	82%	18%
£100,000	91%	9%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	27%	1%	73%



FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Breast cancer: skeletal-related event naive

	QALY	£ total		Δ Cost	ICER
BSC	1.848	CiC information has been removed	0.035	£4340	£124,461
Zoledronic acid	1.875	CiC information has been removed	0.008	-£204	Dominant
Denosumab	1.883	CiC information has been removed	_	_	-
Disodium pamidronate	1.873	CiC information has been removed	0.009	-£3109	Dominant

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
£O	88%	12%	0%
£20,000	98%	2%	0%
£30,000	99%	1%	0%
£40,000	99%	1%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£O	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	1%	0%	0%	99%
£100,000	26%	0%	0%	74%



FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Prostate cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.088	CiC information has been removed	0.039	£2786	£71,920
Zoledronic acid	1.116	CiC information has been removed	0.011	-£121	Dominant
Denosumab	1.126	CiC information has been removed	-	-	-
CiC, commercial-in-c	onfidence.				
WTP/QALY		Denosumab	Zoledror	nic acid	
£0		86%	14%		
£20,000		99%	1%		
£30,000		99%	1%		
£40,000		99%	1%		
£100,000		100%	0%		

WTP/QALY	Denosumab	Zoledronic acid	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	3%	0%	97%
£100,000	81%	0%	19%



FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Other solid tumours plus non-small cell lung cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.715	CiC information has been removed	0.024	£1702	£71,883
Zoledronic acid	0.731	CiC information has been removed	0.008	£45	£5848
Denosumab	0.739	CiC information has been removed	-	-	-

WTP/QALY	Denosumab	Zoledronic acid
£0	31%	69%
£20,000	84%	16%
£30,000	93%	7%
£40,000	96%	4%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	1%	0%	99%
£40,000	6%	0%	94%
£100,000	76%	0%	24%



FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Non-small cell lung cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.453	CiC information has been removed	0.014	£1578	£109,934
Zoledronic acid	0.461	CiC information has been removed	0.006	£16	£2620
Denosumab	0.467	CiC information has been removed	-	-	-

WTP/QALY	Denosumab	Zoledronic acid
£0	44%	56%
£20,000	75%	25%
£30,000	80%	20%
£40,000	83%	17%
£100,000	90%	10%

WTP/QALY	DEN	ZOL	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	2%	0%	98%
£100,000	42%	1%	57%



FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Breast cancer: skeletal-related event experienced

	QALY	£ total		Δ Cost	ICER
BSC	1.778	CiC information has been removed	0.017	£4146	£241,181
Zoledronic acid	1.790	CiC information has been removed	0.005	-£298	Dominant
Denosumab	1.795	CiC information has been removed	_	_	-
Disodium pamidronate	1.785	CiC information has been removed	0.010	-£3470	Dominant

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
£O	94%	6%	0%
£20,000	98%	2%	0%
£30,000	99%	1%	0%
£40,000	99%	1%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£O	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	1%	0%	0%	99%
£100,000	7%	0%	0%	94%



FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Prostate cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.996	CiC information has been removed	0.027	£2695	£101,216
Zoledronic acid	1.017	CiC information has been removed	0.006	-£132	Dominant
Denosumab	1.023	CiC information has been removed	-	_	-

WTP/QALY	Denosumab	Zoledronic acid
£0	86%	14%
£20,000	97%	3%
£30,000	98%	2%
£40,000	99%	1%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£O	0%	0%	100%
£20,000	0%	0%	100%
£30,000	1%	0%	100%
£40,000	2%	0%	98%
£100,000	44%	1%	56%



FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Other solid tumours plus non-small cell lung cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.689	CiC information has been removed	0.011	£1825	£159,757
Zoledronic acid	0.696	CiC information has been removed	0.004	£63	£14,373
Denosumab	0.700	CiC information has been removed	_	_	-

WTP/QALY	Denosumab	Zoledronic acid
£0	26%	74%
£20,000	59%	41%
£30,000	71%	29%
£40,000	80%	20%
£100,000	94%	6%

WTP/QALY	Denosumab	Zoledronic acid	BSC
fO	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	0%	0%	100%
£100,000	14%	0%	86%



FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Non-small cell lung cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.425	CiC information has been removed	0.010	£1572	£157,231
Zoledronic acid	0.432	CiC information has been removed	0.003	£41	£12,415
Denosumab	0.435	CiC information has been removed	_	-	-

WTP/QALY	Denosumab	Zoledronic acid
£0	33%	67%
£20,000	59%	41%
£30,000	66%	34%
£40,000	72%	28%
£100,000	84%	16%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	20%	1%	79%



FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.



FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)